Rachel Abbott, a biochemist and expert on cancer immunotherapy targets, has joined Pan Cancer T BV as chief scientific officer. Based in the Netherlands, Pan Cancer T is developing T cell receptor T cell therapies to treat solid tumours. Dr Abbott succeeds Reno Debets, a co-founder of the company who is returning to the Erasmus University Medical Center.
Dr Abbott most recently led T cell receptor and dark antigen research at Enara Bio Ltd in the UK. Prior to this, she led pipeline cell biology at Adaptimmune Therapeutics Plc.
She holds DPhil and MBiochem degrees from the University of Oxford, UK.
Pan Cancer T announced the appointment on 17 January 2023.
Copyright 2023 Evernow Publishing Ltd